Edward Agyare, Ph.D.

Division Director and Associate Professor Pharmaceutical Sciences
LOCATION: Tallahassee, Dyson Room 228
EMAIL: edward.agyare@famu.edu
PHONE: 850-599-3581

EDUCATION
Biosketch

Edward Agyare, Ph.D., serves as the associate professor, Basic Pharmaceutical Sciences, and as the division director of Pharmaceutical Sciences.

Dr. Agyare’s laboratory works with a variety of nanoparticles for imaging and chemotherapy. He has previously loaded Magnevist®, a contrast agent, into liposomal nanoparticle for magnetic resonance imaging (MRI) of pancreatic cancer in vivo and performed the first comprehensive biodistribution and pharmacokinetic analysis of such a nanoprobe. He has also developed techniques to enhance the signal-to-noise ratio of tumor-imaging using such nanoprobes. Dr. Agyare’s previous work with drug delivery system has focused extensively on using gemcitabine loaded-thermosensitive liposomal nanoparticle-mediated hyperthermia to sensitize tumors to gemcitabine and defined a novel dual mechanism of action involving anti-hypoxic and vascular disrupting properties of this approach. In anticipation of clinical translation of this paradigm, his laboratory develops a theranostic nanoparticle that combines contrast agent and modified existing anticancer agent as one unit that would have the ability for early detection and tumor growth suppression.

 

Fellowship
    • Postdoctoral Fellow: The University of Texas, MD Anderson Cancer Center, Houston, Texas.
    • Visiting Fellow: Mayor Clinic Graduate School, Rochester, MN.
    • Visiting Scientist: The University of Texas, MD Anderson Cancer Center, Houston, Texas
Areas of Expertise
    • Drug Delivery
    • Tumor Targeting
    • Nanotechnology and Nanomedicine
Research Interest
  • Mechanisms of nanotechnology-based modified anticancer drug delivery, with emphasis on understanding how various biological barriers influence the effectiveness of delivery systems.

  • Development of theranostics for the early diagnosis and treatment of pancreatic and colorectal cancers.

Selective Publications
  • Smith, T. Affram, K. Bulumko, E. Agyare, E. (2018) Evaluation of in-vitro cytotoxic effect of 5-FU loaded-chitosan nanoparticles against spheroid models. J Nat Sci., 4(10). PMCID: PMC 6364702

  • Scarton L, Yoon S, Oh S, Agyare E, Trevino J, Han B, Lee E, Setiawan VW, Permuth JB, Schmittgen TD, Odedina FG, Wilkie DJ (2018). Pancreatic Cancer Related Health Disparities: A Commentary. Cancers (Basel) 10(235) PMCID: PMC 6070801

  • Kevin Affram, Udofot Ofonime, Renee Reams, Sunil. Krishnan, Mandip. Sachdeva, Jens Rosenberg, Edward Agyare (2017). Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. PLoS ONE: 12(9):e0185116. PMCID: PMC5608370

  • Udofot, O., Affram K., T. Smith, B. Tshabe, S. Krishnan, M. Sachdeva, E. Agyare (2016). Pharmacokinetics, biodistribution, and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. Journal of Nature and Science (JNSCI), 2(1):e171: PMCID: PMC4869888

  • Kevin Affram, Ofonime Udofot, Edward K. Agyare. Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines. Integr Cancer Sci Therapy, 2015. 2(2): 133-142 PMID: 26090123, PMCID:PMC4469203